Core Insights - The RNAi therapy market is projected to reach a global market size of $25 billion by 2030, with a significant share in common diseases and tumors, accounting for 54% of the total market size [3] - The Chinese RNAi therapy market is expected to grow from approximately $4 million in 2022 to over $300 million by 2025, with a CAGR exceeding 300%, and is projected to reach around $3 billion by 2030 [3][1] Group 1: Market Trends - The global RNAi therapy market has seen a substantial increase from $12 million in 2018 to $362 million in 2020, with a CAGR of 449.2% [3] - The recent surge in small nucleic acid drugs has led to a wave of business development (BD) activities, with major pharmaceutical companies like Novartis, AZ, and others investing heavily in this field [4] Group 2: Technological Advancements - Recent breakthroughs in small nucleic acid drug design have addressed challenges such as vascular degradation, immune activation, and delivery mechanisms, enhancing the potential for effective treatments [2] - Successful approvals of multiple small nucleic acid drugs, such as Nusinersen with $1.6 billion in sales, Vutrisiran with $970 million (yoy +73%), and Inclisiran with $750 million (yoy +112%), demonstrate their efficacy and safety [2] Group 3: Investment Opportunities - The current landscape shows a limited number of approved small nucleic acid drugs, with 22 drugs expected to be approved by mid-2025, indicating a potential for market expansion [5] - Companies with innovative pipelines and technology platforms, such as Yuyuan Pharmaceutical and Chengdu XianDao, are highlighted as potential investment targets [6]

Investment Rating - The report suggests a positive investment opportunity in the small nucleic acid drug industry, highlighting its unique advantages and potential for growth [2]. Core Insights - Small nucleic acid drugs possess unique advantages such as broad target accessibility, strong specificity, high development efficiency, and prolonged dosing intervals, which significantly enhance patient compliance and open up potential clinical demand [2]. - Recent technological breakthroughs in small nucleic acid drug design have addressed challenges such as vascular degradation, immune activation, and delivery difficulties, leading to successful market approvals and showcasing excellent efficacy and safety [2]. - The global market for RNAi therapies is projected to grow from $12 million in 2018 to $25 billion by 2030, with a CAGR of 449.2%, indicating a rapid expansion phase for small nucleic acid drugs [2]. - Major multinational corporations (MNCs) are increasingly investing in the small nucleic acid field, with significant collaborations and development projects emerging, particularly in China [2]. - The report emphasizes the limited number of approved small nucleic acid products, suggesting that Chinese companies have the potential to capture a significant share of the global market [2]. Summary by Sections 1. Introduction and Core Technology of Small Nucleic Acid Drugs - Small nucleic acid drugs are defined as short-chain nucleic acids composed of dozens of nucleotides, targeting RNA to regulate protein expression [10]. - The report outlines the unique characteristics of small nucleic acid drugs, including their ability to target a wide range of disease-related genes and their potential to become a third major class of therapeutics after small molecules and antibody drugs [19]. 2. Market Overview of Small Nucleic Acid Drugs - The small nucleic acid drug market is experiencing rapid growth, with the global market size expected to reach $52.47 billion in 2024, reflecting an 18% year-on-year increase [50]. - The report forecasts that the RNAi therapy market in China will grow from approximately $4 million in 2022 to over $300 million by 2025, with a CAGR exceeding 300% [50]. 3. Disease Areas for Small Nucleic Acid Drugs - The report identifies genetic rare diseases as the most common indication for approved small nucleic acid drugs, with 16 out of 22 approved products targeting this area [51][52]. 4. Leading Overseas Companies in Small Nucleic Acid - The report highlights several leading companies in the small nucleic acid space, including Alnylam, Ionis, and Arrowhead, which are at the forefront of innovation and development [2]. 5. Recommended Companies to Watch - The report suggests monitoring companies with proprietary technology platforms and innovative pipeline layouts, such as Yuyuan Pharmaceutical, Rejuve Biotech, and others, as potential investment opportunities [2].

Market Overview - The Hang Seng Index closed down 185 points, marking a cumulative decline of 385 points over two days, with a final closing value of 26,159 points [3] - The total market turnover was 29.46 billion HKD, with a net outflow of 4.069 billion HKD from northbound trading [3] Stock Performance - Among 88 blue-chip stocks, 67 experienced declines, with notable drops including: - CSPC Pharmaceutical Group down 4.7% to 9.47 HKD - China Biologic Products down 4.5% to 8.14 HKD - WuXi AppTec down 3.3% to 109.7 HKD - BYD down 3.1% to 106.3 HKD - New Oriental Education saw an increase of 1.9% to 40.64 HKD, and CITIC Limited rebounded by 1.5% to 11.5 HKD, being the strongest blue chips [4] Debt Issuance - Bank of China assisted the Shenzhen Municipal Government in issuing offshore RMB local government bonds in Hong Kong, raising a total of 4 billion RMB. The bonds include 2-year, 5-year, and 10-year maturities with interest rates of 1.61%, 1.8%, and 2.08% respectively [7] - The issuance attracted significant interest, with a peak order book size of 18.67 billion RMB and an order multiple of 4.7 times [7] Green Finance Initiatives - The Hong Kong Stock Exchange signed a memorandum of cooperation with carbon trading centers in Guangzhou, Shenzhen, and Macau to enhance knowledge sharing and cooperation in the green finance ecosystem within the Greater Bay Area [8] E-commerce Regulation - The State Administration for Market Regulation reported that the online retail sales in China reached 7.43 trillion RMB in the first half of the year, growing by 8.5% year-on-year, with live e-commerce playing a significant role. However, issues of false marketing and counterfeit products were highlighted as prominent problems in the sector [9] Corporate Developments - Fantasia Holdings announced that 84% of its existing bondholders have supported the restructuring agreement, extending the deadline for creditors to join the plan [12] - Postal Savings Bank of China will absorb its wholly-owned subsidiary, Postal Huinong Bank, to optimize management and business structure, with no significant impact on its financial status [13] - China Resources Land announced the resignation of its CFO and the appointment of new executives [14] - Jiufang Zhitu Holdings is investing in EX.IO to expand its digital asset business, leveraging the resources of the virtual asset trading platform [15]

建议关注：①全球大单品：百济神州(06160)，科伦博泰生物(06990)，信达生物(01801)，康方生物 (09926)，三生制药(01530)，百利天恒(688506.SH)，新诺威(300765.SZ)，石药集团(01093)，翰森制药 (03692)，中国生物制药(01177)，一品红(300723.SZ)，映恩生物(09606)； ②全球BIC潜力：益方生物(688382.SH)，泽璟制药(688266.SH)，基石药业(01592)，苑东生物 (688513.SH)，科济药业(02171)，来凯医药(02105)，复宏汉霖(02696)，再鼎医药(09688)，和黄医药 (00013)，药捷安康(02617)，加科思(01167)，歌礼制药(01672)； ③国内大单品：舒泰神(300204.SZ)，艾力斯(688578.SH)，云顶新耀(01952)，恒瑞医药(600276.SH)，贝 达药业(300558.SZ)，华领医药(02552)； ④资产价值：和铂医药(02142)，和誉(02256)。 立足现在：进军全球商业化，大量优质项目将继续推高产业发展 中国创新药行业已形成以领头企业为引领、 ...

Core Viewpoint - The pharmaceutical sector in both A-shares and Hong Kong stocks experienced significant declines, particularly in innovative drugs and CXO concepts, despite a slight recovery towards the end of the trading session [1][3]. A-Share Market Summary - The largest medical ETF in A-shares (512170) fell by 1.81%, marking its fourth consecutive decline, with a trading volume increase of over 50% to 846 million yuan [1]. - The pharmaceutical sector remained sluggish, with both innovative drugs and traditional Chinese medicine concepts declining, as evidenced by the only drug ETF (562050) dropping 1.61% for three consecutive days [1]. Hong Kong Market Summary - In the Hong Kong market, the innovative drug ETF (520880) saw a decline of 1.42% after a brief rebound, with a trading volume of 327 million yuan [3]. - Among the 37 constituent stocks of the Hong Kong innovative drug ETF, 31 stocks fell, with the largest drop being 5.12% for Yimeng Biotechnology [3]. Market Dynamics - Despite the downturn, both the A-share medical ETF and the Hong Kong innovative drug ETF are trading at a premium, indicating an influx of capital seeking to buy at lower prices [6]. - The Hong Kong innovative drug ETF has attracted nearly 680 million yuan over 14 consecutive trading days from September 2 to 19 [6]. Policy and Industry Outlook - The National Healthcare Security Administration recently released the 11th batch of centralized drug procurement documents, emphasizing quality assurance and reasonable profit margins for pharmaceutical companies [6]. - The fund manager of the Hong Kong innovative drug ETF believes that the new procurement policies will support innovation in the pharmaceutical sector and enhance the industry's profitability [6]. Investment Strategy - The fund manager suggests a potential rotation towards large-cap blue-chip companies in the mid-term, while small-cap companies may lose investor interest if they fail to deliver performance [7]. - A balanced investment approach is recommended, combining innovative drugs with sectors like medical devices and healthcare services [7]. ETF Characteristics - The Hong Kong innovative drug ETF (520880) focuses exclusively on innovative drug research and development, while the medical ETF (512170) includes a broader range of healthcare sectors [8]. - The medical ETF is the largest in the market, with a scale of 26.5 billion yuan, while the drug ETF is the only one tracking the China Pharmaceutical Index [9].

Group 1 - The Hang Seng Index experienced a weak fluctuation, closing down by 0.7%, while the Hang Seng Tech Index fell by 1.45% [1] - The consumer, real estate, and healthcare sectors saw widespread declines, with companies like CSPC Pharmaceutical Group and Vanke Enterprises dropping nearly 5% [1] - Most tech stocks retreated, with Baidu Group declining by over 5% [1] Group 2 - Companies like Constellation Brands and Weigang Yuma both surged by over 20%, as they proposed discounted placements exceeding 15% [1]

Group 1: Market Performance - The Hong Kong Innovation Drug ETF (159570) experienced a decline of 1.48% with a trading volume of nearly 2 billion CNY on September 23, 2025, and has seen a net inflow of over 15 billion CNY in the past 10 days [1] - As of September 22, 2025, the total size of the Hong Kong Innovation Drug ETF (159570) exceeded 21.6 billion CNY, leading its peers in both size and liquidity [1] - The underlying index components of the ETF mostly showed negative performance, with notable declines in China Biologic Products and CSPC Pharmaceutical Group, while Kangfang Biotech rose over 4% due to positive research news [1] Group 2: Industry Trends - Morgan Stanley noted that the total market capitalization of Chinese biotech stocks listed in Hong Kong has increased by 154% year-to-date, significantly outperforming the Hang Seng Index's 34% increase, indicating a major shift in market recognition of local pharmaceutical innovation capabilities [2] - The pharmaceutical sector is entering a new development phase driven by innovation, with major companies showing stable growth and transitioning from generic to innovative drugs [3][4] - The pharmaceutical industry is expected to benefit from ongoing policy support for innovative drugs, with recent announcements from the National Medical Insurance Bureau indicating a focus on optimizing drug procurement and supporting innovative products [5] Group 3: Company Performance - Hengrui Medicine reported a revenue of 15.76 billion CNY for H1 2025, a year-on-year increase of 15.88%, with a net profit of 4.45 billion CNY, up 29.67% [4] - China Biologic Products achieved a revenue of 17.58 billion CNY in H1 2025, reflecting a year-on-year growth of 9.8%, with a net profit increase of 13.10% [4] - Innovent Biologics demonstrated significant growth in innovative drug revenue, with a 26% increase in H1 2025, contributing to a 32% rise in net profit [4] Group 4: Future Outlook - The pharmaceutical sector is expected to continue benefiting from improved global liquidity and supportive national policies for innovation, with a focus on emerging technologies and international competitiveness [7] - The industry is anticipated to see long-term growth opportunities, particularly in innovative drugs and medical devices, as well as potential challenges associated with international expansion [7] - The recent adjustments in the national drug procurement policy are expected to stabilize the market for generic drugs, reducing the impact of price competition on the sector [5]

9月23日，港股三大指数集体收跌，继上周四刷新阶段新高后持续回落，恒生科技指数一度大跌至2.6%，最终收跌1.45%，恒生指数跌0.7%险守26000点，国 企指数跌0.86%。 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | | 恒生科技指数 | | 6167.06 | -90.85 | -1.45% | | 800700 | Marrow | | | | | 国企指数 | | 9290.34 | -80.39 | -0.86% | | 800100 | Municipan | | | | | 恒生指数 | | 26159.12 | -185.02 | -0.70% | | 800000 | Manrow | | | C 簡容口 | | 行业热力图 v | 频流板块 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 汽车 | 生物技术 -1.02% | 地产发展商 -1.76% | | 药品 -2.36% | | 银行 | + ...

Market Overview - Hong Kong's three major indices opened slightly higher but fell throughout the day, with the Hang Seng Index closing down 0.7% at 26,159.12 points and a total turnover of HKD 294.56 billion [1] - The Hang Seng Tech Index dropped 1.45% to 6,167.06 points, indicating weakness in the tech sector [1] Blue Chip Performance - HSBC Holdings (00005) rose 1.31% to HKD 108.6, contributing 28.6 points to the Hang Seng Index [2] - Other notable blue chips included New Oriental-S (09901) up 1.85% and CITIC Limited (00267) up 1.5%, while CSPC Pharmaceutical Group (01093) and China Biologic Products (01177) saw declines of 4.73% and 4.46%, respectively [2] Sector Highlights - Large tech stocks generally declined, with Tencent down 0.86% and Xiaomi dropping over 1%, while Alibaba saw a slight increase of 0.13% [3] - Gold stocks continued to rise, with Tongguan Gold (00340) up 6.38% as international gold prices reached new highs, with London gold hitting USD 3,759.16 per ounce [3] - Banking stocks showed resilience, with Chongqing Rural Commercial Bank (03618) up 2.94% and other banks also posting gains, reflecting improved performance expectations in the banking sector [4] Cryptocurrency Sector - Cryptocurrency-related stocks faced significant declines, with Guotai Junan International (01788) down 11.57% following regulatory actions from the China Securities Regulatory Commission [5][6] Notable Stock Movements - Yunzhihui Technology (01037) surged 103.23% after announcing a strategic partnership in humanoid robotics [7] - Different Group (06090) saw a 43.96% increase on its debut, focusing on high-end parenting products [8] - Shankai Holdings (00412) rose 22.25% after announcing a share buyback plan [9] - Liqin Resources (02245) reached a new high, up 14.29%, due to favorable cobalt export policies in the Democratic Republic of Congo [10] - China Rare Earth Holdings (03788) increased by 12.53% after announcing a share issuance to support gold mining projects [11] - Zhejiang Shibao (01057) rose 12.27% as it prepares for mass production of advanced steering technologies [12]

Industry Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The Chinese innovative drug industry has established a trend towards global commercialization, supported by a pyramid structure of leading and quality enterprises, indicating strong sustainability in industry development [2]. - The underlying logic of the current cycle is that Chinese innovative drugs possess global competitiveness, shifting from domestic sales to international licensing and commercialization, thus opening up commercial space and maturing the ecosystem [2]. - The focus on differentiated mechanisms or high clinical value "good molecules" remains a core interest for international buyers, with early data being crucial for entering licensing windows [2]. Current Situation - The Chinese innovative drug industry is entering a phase of realization, driven by support from capital markets, policies, and talent [3]. - The industry has developed self-sustaining capabilities through business development (BD) licensing and drug commercialization [3]. - Comprehensive policy support for "true innovation" has been established, enhancing the industry's growth [3]. Future Outlook - Continued collaboration among academia, industry, and research will enhance the output of first-in-class (FIC) molecules, with China becoming one of the most efficient countries in the drug development pathway [4]. - Higher innovation levels are expected to further unlock commercial value, indicating a promising future for the industry [4]. Investment Recommendations - Focus on global blockbuster products: companies such as BeiGene, Kelun-Biotech, Innovent Biologics, and others are highlighted as key players [5]. - Attention to global best-in-class (BIC) potential companies, including EdiGene, Zai Lab, and others, is recommended [5]. - Domestic blockbuster products and asset values of companies like Hengrui Medicine and others are also suggested for consideration [5].